The AMR Action Fund announces its first non-industry investments, raising an additional US$140 million toward addressing antimicrobial resistance (AMR)
Today, the AMR Action Fund announced its first initial close with non-pharmaceutical industry investments of more than US$140 million from the Boehringer Ingelheim Foundation, the European Investment Bank (supported by the European Commission), and the Wellcome Trust. This adds to the initial investment from more than 20 leading biopharmaceutical companies that established the Fund as announced in July 2020. With this significant financial commitment from global foundations and development banks, the AMR Action Fund becomes the world’s largest public-private partnership supporting the development of new antibiotics. It demonstrates the type of commitment and collaboration across sectors that is urgently needed to address the global threat of antibiotic-resistant infections – also called antimicrobial resistance, or AMR.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.